Individualizing chemotherapy for canine lymphoma based on ex vivo drug sensitivity test

March 19, 2020

*This event was postponed due to COVID-19.

Presentation Detail

  • Speaker: Sungwon Lim, PhD, CEO & Co-Founder of ImpriMed, Inc.
  • Date: March 19, 2020

Research Abstract

Introduction
For a life-threatening disease like cancer, optimal treatment may need to be personalized for each patient. We developed a functional precision medicine platform based on a novel chemosensitivity assay to identify effective drugs most likely to benefit an individual canine lymphoma patient, ultimately enabling veterinary oncologists to treat lymphoma with an individualized regimen. This study evaluated the correlation between our ex vivo data-driven prediction and reported responses in a series of canine lymphoma patients.

Methods
We performed our ex vivo drug sensitivity assay on live cancer cells from fresh fine needle aspirates taken from affected lymph nodes of canine lymphoma patients. The drug panel included the seven most common chemotherapy drugs for canine lymphoma treatment: doxorubicin, cyclophosphamide, vincristine, prednisone, lomustine, TANOVEA-CA1, and L-asparaginase. 180 correlations between drug response prediction and clinical outcome were evaluated retrospectively in 80 canine lymphoma patients provided by 14 clinical sites, by collecting the patient’ s treatment history and the post-treatment clinical outcomes 60-90 days after our prediction report.ResultsEach of the 80 lymphoma patients showed a unique drug response profile from the ex vivo chemosensitivity test. The positive predictive value of the test was 82.4% and the negative predictive value was 80.2% with 74.4% sensitivity and 86.7% specificity.

Conclusion
This study proved the need for individualizing chemotherapy for canine lymphoma patients by revealing unique drug response profile of each patient. The drug sensitivity test developed in this study showed high positive and negative predictive values ex vivo.

Clinical significance of the results
The ex vivo drug sensitivity test developed in this study may help improving treatment outcomes in individual canine lymphoma patients by providing predictive information on chemotherapy sensitivity.

Presentations

Increased survival and remission rates in prospective study of relapsed B-cell lymphoma patients treated by oncologists using ImpriMed's AI predictions

Veterinary Cancer Society Annual Conference 2023
Learn More →

Canine Lymphoma Diagnostics Past, Present and Future: How AI technology and genetics are pushing the boundaries in veterinary medicine

Veterinary Cancer Society Annual Conference 2023
Learn More →

Impact of AI on clinical practice and outcome

Veterinary Cancer Society Annual Conference 2023
Learn More →

Identification of drug response biomarkers for canine lymphoma in large-scale NGS screen

Veterinary Cancer Society Annual Conference 2023
Learn More →

ImpriMed: AI-driven Personalized Medicine for Pet Cancer Care

Veterinary Cancer Society-Veterinary Society of Surgical Oncology Collaborative Conference 2023
Learn More →

Reinventing precision medicine: from dogs to humans

Precision Medicine World Conference 2023
Learn More →

Identification of Novel Predictive Biomarkers of Anticancer Drug Responses in Canine B-Cell Lymphoma Using Targeted NGS

Veterinary Cancer Society Annual Conference 2022
Learn More →

ImpriMed Research Update

Veterinary Cancer Society Annual Conference 2022
Learn More →

Drugs predicted to be effective using artificial intelligence (AI) double the clinical response rate in canines with relapsed B-cell lymphoma

Veterinary Cancer Society Mid-Year Conference 2022
Learn More →

ImpriMed Research Update

Veterinary Cancer Society Mid-Year Conference 2022
Learn More →

Precision medicine for pet cancer care

Animal Health, Nutrition and Technology Innovation Europe 2022
Learn More →

Predicting dynamic clinical outcomes of (L-)CHOP chemotherapy for canine lymphoma patients using an artificial intelligence model

Veterinary Cancer Society Annual Conference 2021
Learn More →

ImpriMed: Experiences from the eyes of an oncologist in clinical practice

Veterinary Cancer Society Annual Conference 2021
Learn More →

Predicting likelihood of in vivo chemotherapy response in canine lymphoma using ex vivo drug sensitivity and immunophenotyping data in a machine learning model

Veterinary Cancer Society Annual Conference 2020
Learn More →

ImpriMed: A data-driven, personalized chemotherapy drug testing service for canine blood cancer patients

Veterinary Cancer Society Annual Conference 2021
Learn More →

From dog to human: precision medicine for comparative oncology

Precision Medicine World Conference 2020
Learn More →

ImpriMed: precision medicine for pet cancer care

NYC Oncology Conference 2019
Learn More →

Individualizing chemotherapy for canine lymphoma based on ex vivo drug sensitivity test

Veterinary Cancer Society Annual Conference 2019
Learn More →